RU2644258C2 - Способы и материалы для лечения болезни помпе - Google Patents

Способы и материалы для лечения болезни помпе Download PDF

Info

Publication number
RU2644258C2
RU2644258C2 RU2014139953A RU2014139953A RU2644258C2 RU 2644258 C2 RU2644258 C2 RU 2644258C2 RU 2014139953 A RU2014139953 A RU 2014139953A RU 2014139953 A RU2014139953 A RU 2014139953A RU 2644258 C2 RU2644258 C2 RU 2644258C2
Authority
RU
Russia
Prior art keywords
amino acid
polypeptide
mannose
seq
gaa
Prior art date
Application number
RU2014139953A
Other languages
English (en)
Russian (ru)
Other versions
RU2014139953A (ru
Inventor
Воутер ФЕРВЕКЕН
Кейтлин Камилла Телефвор Алида Мария ПИЕНС
Ян Робет Лудо СТАУТ
Гвенда Ноэлла ПИНАЭРТ
Original Assignee
Оксирейн Юкей Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оксирейн Юкей Лимитед filed Critical Оксирейн Юкей Лимитед
Publication of RU2014139953A publication Critical patent/RU2014139953A/ru
Application granted granted Critical
Publication of RU2644258C2 publication Critical patent/RU2644258C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
RU2014139953A 2012-03-15 2013-03-14 Способы и материалы для лечения болезни помпе RU2644258C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611485P 2012-03-15 2012-03-15
US61/611,485 2012-03-15
PCT/IB2013/000912 WO2013136189A2 (en) 2012-03-15 2013-03-14 Methods and materials for treatment of pompe's disease

Publications (2)

Publication Number Publication Date
RU2014139953A RU2014139953A (ru) 2016-05-20
RU2644258C2 true RU2644258C2 (ru) 2018-02-08

Family

ID=48626475

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014139953A RU2644258C2 (ru) 2012-03-15 2013-03-14 Способы и материалы для лечения болезни помпе

Country Status (10)

Country Link
US (2) US9249399B2 (https=)
EP (2) EP3628326B1 (https=)
JP (1) JP6194324B2 (https=)
KR (2) KR102028228B1 (https=)
CN (1) CN104379162B (https=)
AU (1) AU2013234042B2 (https=)
BR (1) BR112014022624A2 (https=)
CA (1) CA2867237C (https=)
RU (1) RU2644258C2 (https=)
WO (1) WO2013136189A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120107A2 (en) 2007-04-03 2008-10-09 Oxyrane (Uk) Limited Glycosylation of molecules
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
WO2012042387A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
CA3008975A1 (en) 2015-12-24 2017-06-29 Oxyrane Uk Limited Human alpha-n-acetylgalactosaminidase polypeptide
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
IL325155A (en) * 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
TWI759291B (zh) * 2016-03-30 2022-04-01 美商阿米庫斯醫療股份有限公司 用於選擇高m6p重組蛋白之方法
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20220125892A1 (en) 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
CA3207917A1 (en) * 2021-02-11 2022-08-18 Hung Do Recombinant human acid alpha-glucosidase and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005123986A (ru) * 2003-01-22 2007-02-27 Гликарт Биотекнолоджи АГ (CH) Конструкции слияния и их применение для получения антител с повышенными аффинностью связывания fc-рецептора и эффекторной функцией
EA012617B1 (ru) * 2005-03-24 2009-10-30 ДСМ АйПи АССЕТС Б.В. Способ микробиального производства ценного соединения
WO2011039634A2 (en) * 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
JPS5754588A (en) 1980-09-19 1982-04-01 Eiji Ichijima Alpha-mannosidase
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5834251A (en) 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
WO1997044470A1 (en) 1996-05-21 1997-11-27 Novo Nordisk A/S Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
IL127583A0 (en) 1996-07-05 1999-10-28 Novo Nordisk As Method for the production of polypeptides
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
ATE262041T1 (de) 1997-04-23 2004-04-15 Vlaams Interuniv Inst Biotech Regulationssystem für induzierbare expression von gene mit lambda-ähnlichen promotoren
US7442772B2 (en) 1997-12-03 2008-10-28 Genentech, Inc. Antibodies to PRO361 polypeptide
WO1999037758A2 (en) 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
WO2001042462A2 (en) 1999-12-08 2001-06-14 National University Of Singapore Phospholipase a2 inhibitory peptides from python reticulatus
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
DK1283265T3 (da) 2000-05-17 2009-11-09 Mitsubishi Tanabe Pharma Corp Fremgangsmåde til fremstilling af protein med reduktion af mannosephosphat i sukkerkæden og glycoprotein fremstillet derved
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
EP2267135A3 (en) 2000-06-30 2011-09-14 Vib Vzw Protein glycosylation modification in pichia pastoris
KR100386836B1 (ko) 2000-08-31 2003-06-09 동국제약 주식회사 재조합 인체 부갑상선 호르몬을 생산하는 형질전환효모 및재조합 인체 부갑상선 호르몬의 생산방법
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4774496B2 (ja) 2001-06-14 2011-09-14 独立行政法人産業技術総合研究所 α−マンノシダーゼ
JP4742191B2 (ja) 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
DK1438400T3 (da) 2001-10-01 2009-10-05 Dyax Corp Flerkædede eukaryote display-vektorer og anvendelser deraf
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
JP4820055B2 (ja) 2001-12-27 2011-11-24 グライコフィ， インコーポレイテッド 哺乳動物型糖質構造を操作するための方法
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7972809B2 (en) 2002-04-26 2011-07-05 National Institute Of Advanced Industrial Science & Technology Methylotrophic yeast producing mammalian type sugar chain
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
DE60334109D1 (de) 2002-06-29 2010-10-21 Leadbio Inc Yapsin-mangelmutantenstamm von hansenula polymorpha sowie verfahren zur herstellung rekombinanter proteine damit
KR100470978B1 (ko) 2003-01-02 2005-03-10 한국생명공학연구원 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법
AU2012206984B2 (en) 2003-02-11 2015-07-09 Takeda Pharmaceutical Company Limited Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE)
JP4259169B2 (ja) 2003-04-16 2009-04-30 昭和産業株式会社 新規α−１，２−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法
US7259255B2 (en) 2003-06-25 2007-08-21 E. I. Du Pont De Nemours And Company Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast
EP2341128A1 (en) 2003-12-24 2011-07-06 GlycoFi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
CN1922313B (zh) 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
EP1737969B2 (en) 2004-04-15 2018-09-12 GlycoFi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US7465577B2 (en) 2004-04-29 2008-12-16 Glycofi, Inc. Methods for reducing or eliminating α-mannosidase resistant glycans for the production of glycoproteins
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CA2604917A1 (en) 2005-04-14 2007-01-25 Csir Recombinant yeasts for synthesizing epoxide hydrolases
CA2623197A1 (en) 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
US20110076752A1 (en) 2007-02-09 2011-03-31 Medimmune, Llc Antibody library display by yeast cell plasma membrane
WO2008120107A2 (en) 2007-04-03 2008-10-09 Oxyrane (Uk) Limited Glycosylation of molecules
EP2166093B1 (en) 2007-05-18 2015-09-16 Tokyo Metropolitan Institute of Medical Science Pharmaceutical composition for enzyme replacement therapy
CN105274072A (zh) 2008-01-18 2016-01-27 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
EP2245151B1 (en) 2008-02-20 2014-12-24 GlycoFi, Inc. Vectors and yeast strains for protein production
HRP20170698T1 (hr) * 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
EP2401357B1 (en) 2009-02-26 2015-03-25 GlaxoSmithKline LLC Host cells and methods of use
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
US20130096281A1 (en) 2010-01-21 2013-04-18 Oxyrane Uk Limited Methods and compositions for displaying a polypeptide on a yeast cell surface
US20120135461A1 (en) 2010-07-30 2012-05-31 William James Cook Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase
WO2012042387A2 (en) * 2010-09-29 2012-04-05 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
BR112014015933A2 (pt) 2011-12-30 2019-09-24 Oxyrane Uk Ltd métodos e materiais para reduzir a degradação das proteínas recombinantes
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005123986A (ru) * 2003-01-22 2007-02-27 Гликарт Биотекнолоджи АГ (CH) Конструкции слияния и их применение для получения антител с повышенными аффинностью связывания fc-рецептора и эффекторной функцией
EA012617B1 (ru) * 2005-03-24 2009-10-30 ДСМ АйПи АССЕТС Б.В. Способ микробиального производства ценного соединения
WO2011039634A2 (en) * 2009-09-29 2011-04-07 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIJVOET A. G. A. et al., Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, Vol.7, NO.11, pp.1815-1824, 1998. *
HIROKI TATSUMI et al., Cloning and Sequencing of the Alkaline Protease cDNA from Aspergillus oryzae, Vol.52, Issue 7, pp.1887-1888, 1988. *
JOHAN L. K. VAN HOVE et al., High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proceedings of the National Academy of Sciences, Vol.93, NO.1, pp.65-70, 1996. *
MORELAND R. J. et al., Lysosomal Acid alpha-Glucosidase Consists of Four Different Peptides Processed from a Single Chain Precursor, The Journal of Biological Chemistry, Vol.280, No.8, pp.6780-6791, 2005. *
ZHU Y. et al., Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease, Molecular Therapy, Vol.17, NO.6, pp.954-963, 2009. *
ZHU Y. et al., Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease, Molecular Therapy, Vol.17, NO.6, pp.954-963, 2009. BIJVOET A. G. A. et al., Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, Vol.7, NO.11, pp.1815-1824, 1998. JOHAN L. K. VAN HOVE et al., High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proceedings of the National Academy of Sciences, Vol.93, NO.1, pp.65-70, 1996. *

Also Published As

Publication number Publication date
JP2015516148A (ja) 2015-06-11
EP3628326C0 (en) 2024-02-28
KR20140135802A (ko) 2014-11-26
US20160279254A1 (en) 2016-09-29
CA2867237A1 (en) 2013-09-19
WO2013136189A3 (en) 2014-02-20
AU2013234042A1 (en) 2014-10-23
CA2867237C (en) 2024-01-02
US9249399B2 (en) 2016-02-02
WO2013136189A2 (en) 2013-09-19
BR112014022624A2 (pt) 2017-07-11
RU2014139953A (ru) 2016-05-20
KR102028228B1 (ko) 2019-10-04
EP2825193B1 (en) 2019-11-13
JP6194324B2 (ja) 2017-09-06
EP3628326A1 (en) 2020-04-01
HK1200348A1 (en) 2015-08-07
US20130243746A1 (en) 2013-09-19
US10648044B2 (en) 2020-05-12
CN104379162B (zh) 2017-03-15
EP3628326B1 (en) 2024-02-28
CN104379162A (zh) 2015-02-25
AU2013234042B2 (en) 2017-11-02
EP2825193A2 (en) 2015-01-21
KR20190114003A (ko) 2019-10-08

Similar Documents

Publication Publication Date Title
RU2644258C2 (ru) Способы и материалы для лечения болезни помпе
US10392609B2 (en) Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
KR101983572B1 (ko) 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법
US20220204952A1 (en) Production of catalytically active type i sulfatase
EP3393501B1 (en) Human alpha-n-acetylgalactosaminidase polypeptide
HK1200348B (en) Methods and materials for treatment of pompe's disease
HK1171248A (en) Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose